Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

Abstract Background Predicting metastasis in melanoma patients is important for disease management and could help to identify those who might benefit from adjuvant treatment. The aim of this study was to investigate whether the tumor microenvironment-derived protein S100A8/A9 qualifies as prognostic...

Full description

Bibliographic Details
Main Authors: Nikolaus B. Wagner, Benjamin Weide, Mirko Gries, Maike Reith, Kathrin Tarnanidis, Valerie Schuermans, Charlotte Kemper, Coretta Kehrel, Anne Funder, Ramtin Lichtenberger, Antje Sucker, Esther Herpel, Tim Holland-Letz, Dirk Schadendorf, Claus Garbe, Viktor Umansky, Jochen Utikal, Christoffer Gebhardt
Format: Article
Language:English
Published: BMJ Publishing Group 2019-12-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
S100A8/A9
Melanoma
Metastasis
PD-1
Biomarker
Serum
Online Access:http://link.springer.com/article/10.1186/s40425-019-0828-1

Internet

http://link.springer.com/article/10.1186/s40425-019-0828-1

Similar Items